Home › Funds › PAYDEN & RYGEL › DGX
PAYDEN & RYGEL position in DGX
QUEST DIAGNOSTICS INC · Health Care
PAYDEN & RYGEL reported holding 62,340 shares of DGX (QUEST DIAGNOSTICS INC) in its Q3 2026 13F filing — a position valued at US$14.5M, representing 1.14% of its reported portfolio and ranking #38 among its reported holdings. PAYDEN & RYGEL has disclosed DGX holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How PAYDEN & RYGEL's DGX position evolved
PAYDEN & RYGEL first disclosed a stake in DGX in Q2 2025 at 93,600 shares (US$16.8M). The position peaked in Q2 2026 at 92,740 shares, worth US$19.7M. Across 6 filings, PAYDEN & RYGEL increased the stake 2 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 62,340 shares valued at US$14.5M — a reduction of -30,400 shares quarter over quarter.. Notable position changes include a 33% trim in Q3 2026 (shares rose 12% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 93.60K | $16.81M | New |
| Q3 2025 | 94.20K | $17.95M | Add |
| Q4 2025 | 93.40K | $16.21M | Reduce |
| Q1 2026 | 76.60K | $15.01M | Reduce |
| Q2 2026 | 92.74K | $19.66M | Add |
| Q3 2026 | 62.34K | $14.53M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DGX and 13F data
DGX (QUEST DIAGNOSTICS INC) is a Health Care company. 26 other funds we track also report a position in DGX — the largest reported positions include Boston Partners (US$1.08B), EdgePoint Investment Group Inc. (US$476.4M), Grantham, Mayo, Van Otterloo & Co. LLC (US$449.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DGX
- Boston Partners 4.64M sh · $1.08B · Q3 2026
- EdgePoint Investment Group Inc. 2.25M sh · $476.37M · Q2 2026
- Grantham, Mayo, Van Otterloo & Co. LLC 1.93M sh · $449.89M · Q3 2026
- DAVIS SELECTED ADVISERS 1.33M sh · $308.97M · Q3 2026
- M&G Plc 770.10K sh · $179.43M · Q3 2026
More on PAYDEN & RYGEL
FAQ
How long has PAYDEN & RYGEL held DGX?
PAYDEN & RYGEL has disclosed DGX holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
What is PAYDEN & RYGEL's current position in DGX?
As of Q3 2026, PAYDEN & RYGEL holds 62.34K shares of DGX (QUEST DIAGNOSTICS INC), valued at $14.53M, representing 1.14% of its reported portfolio and ranking #38.
Has PAYDEN & RYGEL been buying or selling DGX?
In the latest 13F filing (Q3 2026), PAYDEN & RYGEL reduced its position in DGX. The position peaked in Q2 2026 at 92.74K shares.
Which other funds hold DGX?
Other major institutional holders of DGX include Boston Partners, EdgePoint Investment Group Inc., Grantham, Mayo, Van Otterloo & Co. LLC, among 26 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.